ReviewCancers2026
Rewiring of the Apoptotic Rheostat in HTLV-1 Infection and Adult T-Cell Leukemia/Lymphoma.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Human T-cell leukemia virus type 1 (HTLV-1) is the etiological agent of an aggressive malignancy of mature T-cells termed adult T-cell leukemia/lymphoma (ATLL), as well as a spectrum of chronic inflammatory diseases. A defining feature of HTLV-1 infection is a profound dysregulation of apoptotic pathways, which is a key determinant of long-term viral persistence and favors malignant transformation. This review describes the mechanisms through which HTLV-1 gene products, including Tax and HBZ, reprogram host-cell signaling controlling the "apoptotic rheostat", an integrated network connecting redox metabolism, and response to apoptotic cues and immune pressure. We also highlight emerging therapeutic strategies to restore sensitivity to apoptosis, including BH3-mimetic drugs and rational combination approaches. Deciphering how HTLV-1 reconfigures the apoptotic network provides a conceptual and therapeutic framework for targeting death pathway vulnerabilities in ATLL and potentially other hematological neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.